ChroMedX Corp. Extends Expiry Date of Certain Warrants

TORONTO, ONTARIO – February 22, 2016 – ChroMedX Corp. (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) announces that, in accordance with CSE policies, it intends to extend the expiry date of an aggregate of 8,572,500 previously issued warrants (the "Warrants"). The Warrants were originally issued between July 7, 2014 and September 22, 2014, with original expiry dates ranging from March 5, 2016 to July 7, 2016.

As a result of the extension, the new expiry date for the Warrants will be December 31, 2016.  The exercise price of the Warrants will remain unchanged at $0.25 per share.

 

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

 

Follow ChroMedX Corp.: 

Website: www.chromedx.com

Facebook: facebook.com/ChroMedXcorp

Twitter: www.twitter.com/ChroMedXcorp

 

Investor Relations:

 Shawn Overton

d. 647-528-9344

o. 647-872-9982 ext. 2

TF. 1-844-247-6633 ext. 2

soverton@ChroMedX.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.